Charlène Brault1, Pierre Lévy1, Sarah Duponchel1, Maud Michelet1, Aurèlie Sallé1, Eve-Isabelle Pécheur1, Marie-Laure Plissonnier1, Romain Parent2, Evelyne Véricel3, Alexander V Ivanov4, Münevver Demir5, Hans-Michael Steffen5, Margarete Odenthal6, Fabien Zoulim7, Birke Bartosch2. 1. Inserm U1052, Cancer Research Center of Lyon, University of Lyon, Lyon, France. 2. Inserm U1052, Cancer Research Center of Lyon, University of Lyon, Lyon, France DevWeCan Laboratories of Excellence Network (Labex), France. 3. Université de Lyon, UMR 1060 INSERM CarMeN, IMBL, INSA-Lyon, Lyon, France. 4. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. 5. Clinic for Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany. 6. Institute of Pathology, University of Cologne, Cologne, Germany. 7. Inserm U1052, Cancer Research Center of Lyon, University of Lyon, Lyon, France DevWeCan Laboratories of Excellence Network (Labex), France Hospices civils de Lyon, Lyon, France.
Abstract
OBJECTIVE: Inflammation and oxidative stress drive disease progression in chronic hepatitis C (CHC) towards hepatocellular carcinoma. HCV is known to increase intracellular levels of reactive oxygen species (ROS), but how it eliminates ROS is less well known. The role of the ROS scavenger glutathione peroxidase 4 (GPx4), induced by HCV, in the viral life cycle was analysed. DESIGN: The study was performed using a replicative in vitro HCV infection model and liver biopsies derived from two different CHC patient cohorts. RESULTS: A screen for HCV-induced peroxide scavengers identified GPx4 as a host factor required for HCV infection. The physiological role of GPx4 is the elimination of lipid peroxides from membranes or lipoproteins. GPx4-silencing reduced the specific infectivity of HCV by up to 10-fold. Loss of infectivity correlated with 70% reduced fusogenic activity of virions in liposome fusion assays. NS5A was identified as the protein that mediates GPx4 induction in a phosphatidylinositol-3-kinase-dependent manner. Levels of GPx4 mRNA were found increased in vitro and in CHC compared with control liver biopsies. Upon successful viral eradication, GPx4 transcript levels returned to baseline in vitro and also in the liver of patients. CONCLUSIONS: HCV induces oxidative stress but controls it tightly by inducing ROS scavengers. Among these, GPx4 plays an essential role in the HCV life cycle. Modulating oxidative stress in CHC by specifically targeting GPx4 may lower specific infectivity of virions and prevent hepatocarcinogenesis, especially in patients who remain difficult to be treated in the new era of interferon-free regimens. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Inflammation and oxidative stress drive disease progression in chronic hepatitis C (CHC) towards hepatocellular carcinoma. HCV is known to increase intracellular levels of reactive oxygen species (ROS), but how it eliminates ROS is less well known. The role of the ROS scavenger glutathione peroxidase 4 (GPx4), induced by HCV, in the viral life cycle was analysed. DESIGN: The study was performed using a replicative in vitro HCV infection model and liver biopsies derived from two different CHCpatient cohorts. RESULTS: A screen for HCV-induced peroxide scavengers identified GPx4 as a host factor required for HCV infection. The physiological role of GPx4 is the elimination of lipid peroxides from membranes or lipoproteins. GPx4-silencing reduced the specific infectivity of HCV by up to 10-fold. Loss of infectivity correlated with 70% reduced fusogenic activity of virions in liposome fusion assays. NS5A was identified as the protein that mediates GPx4 induction in a phosphatidylinositol-3-kinase-dependent manner. Levels of GPx4 mRNA were found increased in vitro and in CHC compared with control liver biopsies. Upon successful viral eradication, GPx4 transcript levels returned to baseline in vitro and also in the liver of patients. CONCLUSIONS: HCV induces oxidative stress but controls it tightly by inducing ROS scavengers. Among these, GPx4 plays an essential role in the HCV life cycle. Modulating oxidative stress in CHC by specifically targeting GPx4 may lower specific infectivity of virions and prevent hepatocarcinogenesis, especially in patients who remain difficult to be treated in the new era of interferon-free regimens. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Alexander V Ivanov; Olga A Smirnova; Irina Y Petrushanko; Olga N Ivanova; Inna L Karpenko; Ekaterina Alekseeva; Irina Sominskaya; Alexander A Makarov; Birke Bartosch; Sergey N Kochetkov; Maria G Isaguliants Journal: Viruses Date: 2015-05-29 Impact factor: 5.048
Authors: Georgios Grammatikos; Julia Dietz; Nerea Ferreiros; Alexander Koch; Georg Dultz; Dimitra Bon; Ioannis Karakasiliotis; Thomas Lutz; Gaby Knecht; Peter Gute; Eva Herrmann; Stefan Zeuzem; Penelope Mavromara; Christoph Sarrazin; Josef Pfeilschifter Journal: Int J Mol Sci Date: 2016-06-13 Impact factor: 5.923
Authors: Marina K Kukhanova; Vera L Tunitskaya; Olga A Smirnova; Olga A Khomich; Natalia F Zakirova; Olga N Ivanova; Rustam Ziganshin; Birke Bartosch; Sergey N Kochetkov; Alexander V Ivanov Journal: Oxid Med Cell Longev Date: 2019-09-03 Impact factor: 6.543
Authors: Alessia Virzì; Armando Andres Roca Suarez; Thomas F Baumert; Joachim Lupberger Journal: Cold Spring Harb Perspect Med Date: 2020-01-02 Impact factor: 5.159
Authors: Olga A Smirnova; Olga N Ivanova; Birke Bartosch; Vladimir T Valuev-Elliston; Furkat Mukhtarov; Sergey N Kochetkov; Alexander V Ivanov Journal: Oxid Med Cell Longev Date: 2016-04-20 Impact factor: 6.543
Authors: E Guerriero; F Capone; M Accardo; A Sorice; M Costantini; G Colonna; G Castello; S Costantini Journal: Eur J Histochem Date: 2015-12-01 Impact factor: 3.188
Authors: Alexander V Ivanov; Vladimir T Valuev-Elliston; Daria A Tyurina; Olga N Ivanova; Sergey N Kochetkov; Birke Bartosch; Maria G Isaguliants Journal: Oncotarget Date: 2017-01-17